| Medical and Health Sciences | 2021-2025 | 914 | JP 10 | 99.78 |
| Pathology and Forensic Medicine | Lifetime | 126 | JP 3 | 99.47 |
| Epidemiology | Lifetime | 645 | JP 14 | 99.18 |
| Rheumatology | Lifetime | 311 | JP 5 | 98.72 |
| Pulmonary and Respiratory Medicine | Lifetime | 887 | JP 22 | 98.56 |
| Hematology | Lifetime | 333 | JP 2 | 98.06 |
| Immunology | Lifetime | 939 | JP 36 | 96.77 |
| Medical Genetics | Lifetime | 808 | JP 19 | 90.02 |
| Pathology and Forensic Medicine | 2021-2025 | 48 | JP 3 | 99.01 |
| Epidemiology | 2021-2025 | 226 | JP 7 | 98.33 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 281 | JP 11 | 97.49 |
| Rheumatology | 2021-2025 | 180 | JP 1 | 95.41 |
| Hematology | 2021-2025 | 276 | JP 3 | 88.13 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 8 | JP 1 | 99.64 |
| Autoimmune Bullous Skin Diseases | Lifetime | 23 | JP 4 | 99.58 |
| Systemic Sclerosis and Related Diseases | Lifetime | 34 | JP 3 | 99.57 |
| Platelet Disorders and Treatments | Lifetime | 55 | JP 1 | 99.29 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 67 | JP 2 | 99.45 |
| Eosinophilic Disorders and Syndromes | Lifetime | 61 | JP 1 | 99.31 |
| Blood groups and transfusion | Lifetime | 83 | JP 1 | 99.00 |
| Systemic Lupus Erythematosus Research | Lifetime | 409 | JP 14 | 98.70 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 367 | JP 9 | 98.33 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 462 | JP 13 | 97.76 |
| Mast cells and histamine | Lifetime | 302 | JP 34 | 96.71 |
| Celiac Disease Research and Management | Lifetime | 346 | JP 3 | 95.63 |
| Dermatological and Skeletal Disorders | Lifetime | 249 | JP 23 | 95.34 |
| Dermatologic Treatments and Research | Lifetime | 586 | JP 31 | 94.80 |
| Connective Tissue Growth Factor Research | Lifetime | 144 | JP 22 | 92.80 |
| Vascular Anomalies and Treatments | Lifetime | 367 | JP 18 | 92.00 |
| Skin Diseases and Diabetes | Lifetime | 362 | JP 29 | 90.17 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 584 | JP 28 | 86.03 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 961 | JP 88 | 69.45 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 12 | JP 1 | 99.28 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 8 | JP 1 | 99.42 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 34 | JP 2 | 99.11 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 58 | JP 1 | 97.37 |
| Dermatologic Treatments and Research | 2021-2025 | 111 | JP 2 | 94.70 |
| Mast cells and histamine | 2021-2025 | 92 | JP 4 | 93.23 |
| Connective Tissue Growth Factor Research | 2021-2025 | 13 | JP 1 | 89.62 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 495 | JP 29 | 92.96 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 789 | JP 31 | 85.14 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 912 | JP 29 | 82.95 |
| Blood groups and transfusion | 2021-2025 | 512 | JP 8 | 82.34 |
| Skin Diseases and Diabetes | 2021-2025 | 121 | JP 10 | 75.64 |
| Platelet Disorders and Treatments | 2021-2025 | 981 | JP 28 | 78.32 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 706 | JP 17 | 60.67 |
| Parkinson's Disease and Spinal Disorders | 2021-2025 | 676 | JP 70 | 32.25 |
